我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
4
80.0%
Unknown
1
20.0%
暂无批准数据
- Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May. - The company is developing novel treatments for obesity and eating disorders by targeting the central melanocortin system, specifically MC3 and MC4 receptors that regulate energy balance. - Ferrara brings extensive experience from leading Medeor Therapeutics through Phase 3 cell therapy development and founding NeuroVia as a partner at Novartis Venture Funds. - The leadership change positions Courage to accelerate clinical development of its selective MC4R and MC3R compounds while raising additional seed funding.
